Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Sort descending Date Recommendation Issued
Evra Norgelestromin/ethinyl estradiol Contraceptive, patch Do not list Complete
Iressa Gefitinib Cancer, Lung , non-small cell Do not list Complete
Axert Almotriptan Migraine List in a similar manner to other drugs in class Complete
Replagal Agalsidase alfa Fabry Disease Do not list Complete
Viread Tenofovir disoproxil fumarate HIV infection Do not list Complete
Fabrazyme Agalsidase beta Fabry Disease Do not list Complete
Neulasta Pegfilgrastim Neutropenia List with clinical criteria and/or conditions Complete
Adderall XR Mixed amphetamine salts Attention deficit hyperactivity disorder Do not list Complete
Zavesca Miglustat Gaucher disease Do not list Complete
Pegasys RBV Peginterferon alfa-2a and Ribavirin Hepatitis C, chronic List in a similar manner to other drugs in class Complete